1. Home
  2. BMHL vs SGMT Comparison

BMHL vs SGMT Comparison

Compare BMHL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluemount Holdings Limited Class B Ordinary Shares

BMHL

Bluemount Holdings Limited Class B Ordinary Shares

HOLD

Current Price

$5.62

Market Cap

155.4M

Sector

N/A

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.22

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMHL
SGMT
Founded
2016
2006
Country
Hong Kong
United States
Employees
9
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
155.4M
169.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BMHL
SGMT
Price
$5.62
$7.22
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.13
AVG Volume (30 Days)
2.0K
974.6K
Earning Date
06-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$66.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.72
$4.50
52 Week High
$6.35
$10.06

Technical Indicators

Market Signals
Indicator
BMHL
SGMT
Relative Strength Index (RSI) 47.11 48.28
Support Level $5.58 $7.04
Resistance Level $6.35 $7.39
Average True Range (ATR) 0.26 0.44
MACD -0.10 -0.06
Stochastic Oscillator 40.00 25.00

Price Performance

Historical Comparison
BMHL
SGMT

About BMHL Bluemount Holdings Limited Class B Ordinary Shares

Bluemount Holdings Ltd through its operating subsidiaries, is a Hong Kong-based consulting and advisory, financial services, and luxury timepiece trading provider. The Company provides consulting and advisory services on business development strategies, including seeking suitable transaction projects for business development or diversification and suitable business partners or investors for fund-raising projects. Its services are centered around three core offerings: Business Transformation, Strategy, and Transactions. The Company also sources, buys, and sells brand-new luxury branded timepieces. It operates through two reportable segments: security-related services and asset management, and trading of timepieces, with the trading of timepieces generating maximum revenue.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: